

# Peripheral & Endovenous

## Selected Graphics

**Medtronic**

**2020 Institutional Investor & Analyst Day**

October 14, 2020



INVESTOR DAY 2020

**Mark Pacyna**

Vice President & General Manager, Peripheral Vascular



**Medtronic**

**DRUG COATED  
BALLOON**



**PERCUTANEOUS  
AV FISTULAS  
CREATION**


**Medtronic**



Medtronic



00:52





2M

Dialysis patients  
globally

Medtronic




INVESTOR DAY 2020

**Terry Litchfield, MPH**

President, Access Solutions & Patient Advocate

**More than half of AV Fistulas will fail**



**Medtronic**





1-3

Maintenance interventions per year are often needed to keep their fistula functioning


**Medtronic**



\$5B

Estimated spent  
annually  
on vascular access and  
related complications

**Medtronic**



Medtronic

# IN.PACT AV

first and only DCB  
to meet both safety  
and efficacy endpoints  
in this vessel bed

**Medtronic**



**The IN.PACT™ AV**  
**Drug-Coated Balloon**

Medtronic



# 6 month data

Recently published in  
The New England Journal  
of Medicine

**Medtronic**



56% Fewer interventions  
than PTA

78% Highest reported access  
circuit primary patency

86% Highest reported target  
lesion primary patency

**Medtronic**




"If only one in two patients had an IN.PACT AV drug coated balloon used instead of plain angioplasty during hemodialysis maintenance procedures, **our savings at three years to the Medicare beneficiary population on hemodialysis would be over \$400 million.**"

– **Robert Lookstein, M.D., M.H.C.D.L.**

*Professor of radiology and surgery, executive vice-chair in the Department of Diagnostic, Molecular, and Interventional Radiology at the Icahn School of Medicine at Mount Sinai in New York, New York*






**Medtronic**



Medtronic

## CREATES A DURABLE AV FISTULA WITHOUT OPEN SURGERY



MINIMALLY INVASIVE

ULTRASOUND GUIDED

SINGLE CATHETER VENOUS ACCESS


**Medtronic**



INVESTOR DAY 2020

**Jeffrey Hull, M.D.**

Director of the Richmond Vascular Center and Co-Founder of Avenu Medical



Medtronic



4 weeks

Average fistula maturation time

91.6%

Functional patency at 2 years

**Medtronic**



0 procedure related  
serious adverse events

Single center, retrospective study  
of 234 patients evaluated between  
May 2017 and July 2019

- Journal of Vascular Surgery, April 2020

**Medtronic**



**Medtronic**





JOURNAL OF VASCULAR  
INTERVENTIONAL RADIOLOGY  
**MEDIAN PROCEDURE TIMES**

14 minutes  
**ELLIPSYS**

63 minutes  
**WAVELINQ**

**Medtronic**



AV drug-coated balloon  
& percutaneous creation  
potential addressable  
market

**\$900M**  
in the U.S.

**Medtronic**